Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) announced ... as an independent director of the Company,s Board of ... and served as its CEO until its acquisition by ... $240 million transaction. Recognized as the inventor of the ... AeroScout provided Wi-Fi -based RFID solutions focused on improving ...
(Date:12/13/2014)... 2014 Clarassance, a privately held clinical-stage ... name: Therabron Therapeutics , Inc. The new name ... type of structure in the lungs similar to branches ... develop novel protein therapeutics for the treatment of respiratory ... change the name to mark the company's escalation into ...
(Date:12/13/2014)... QuickSTAT is making significant investments in ... capabilities, and is delighted to announce the opening of ... Life Science clients in the region. , QuickSTAT France, ... will provide 24/7 transportation and logistics services, as well ... specimens, API, following IATA rules and EU GDP guidelines. ...
(Date:12/12/2014)... 11, 2014 InSphero AG, the world’s ... testing, announced today that data presented recently by Genentech ... as a more predictive model system for assessment of ... 2nd Annual Functional Analysis and Screening Technologies (FAST) ... response of InSphero’s 3D InSight™ Human Liver Microtissues ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
... Exchange Symbol: MS, EDMONTON, March 24 /PRNewswire-FirstCall/ - ... treatment of multiple sclerosis (MS), today,announced that Mr. Kevin ... Leaders in the Biotech Industry" Conference in New York., ... 2:00pm (Eastern Time), WHERE: The Millennium Broadway ...
... CLARA, Calif., March 24 Finesse Solutions, LLC, ... sciences process,applications, announces the release of TruFluor(TM), a ... in Philadelphia on March,26, 2008., The TruFluor(TM) ... consisting of a disposable sheath, an optical reader,and ...
... 21 Martek Biosciences,(Nasdaq: MATK ) announced today ... Martek,s patented, vegetarian form of DHA,omega-3 for brain, eye ... of 100 mg per gram of life,sDHA and contains ... and supplement applications where,allergens and labeling are concerns., ...
Cached Biology Technology:BioMS Medical to present at BioCentury Conference 2Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter 2Martek's life'sDHA(TM) Now Available in Protein-free Powder 2Martek's life'sDHA(TM) Now Available in Protein-free Powder 3
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... compound showed significant success in controlling the infectivity and spread ... has been no medicine approved to treat such viruses, which ... immune systems have been weakened. The compound, known ... vast majority of cells in cultures when it was administered ...
... the body measures carbon dioxide and suggests that far from ... role as a biological signalling molecule. Researchers led by ... the University of Warwick have shown that the body senses ... as a receptor for the gas. Connexin 26 is better ...
... 13, 2013) Scientists from the New York Stem ... Center (CUMC) have used stem cells created from the ... syndrometo elucidate an important biochemical pathway for beta-cell failure ... were published today in Diabetes . ...
Cached Biology News:Compound stymies polyomaviruses in lab tests 2Compound stymies polyomaviruses in lab tests 3Carbon dioxide's new-found signalling role could be applied to blood flow, birth and deafness 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 3
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Handles samples from from 75l to 150l...
PKA Sampler Kit 10 mu g each...
Chaperone Sampler Kit 10 mu g each...
Biology Products: